TLX — Telix Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Telix Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	C2022 December 31st	R2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	Final	Final	Final
Revenue
Total Revenue	5.7	111	333	517	804
Cost of Revenue
Gross Profit	3.79	65.8	203	319	382
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	62.2	175	322	461	774
Operating Profit	-56.5	-63.7	11	55.2	29.8
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-60.4	-68.4	2.59	37.9	-5.27
Provision for Income Taxes
Net Income After Taxes	-60.4	-72.2	4.21	33.7	-7.13
Net Income Before Extraordinary Items
Net Income	-60.4	-72.2	4.21	33.7	-7.13
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-60.4	-72.2	4.21	33.7	-7.13
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.214	-0.232	0.014	0.127	-0.02
Dividends per Share